# Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)

> **NCT03921671** · PHASE2 · UNKNOWN · sponsor: **Claudia Proto** · enrollment: 60 (estimated)

## Conditions studied

- Thymic Carcinoma
- Thymoma

## Interventions

- **COMBINATION_PRODUCT:** Ramucirumab

## Key facts

- **NCT ID:** NCT03921671
- **Lead sponsor:** Claudia Proto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-01
- **Primary completion:** 2021-10-09
- **Final completion:** 2024-07-16
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03921671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03921671, "Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03921671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*